Tissue disposition and plasma concentrations of idarubicin after intravesical therapy in patients with bladder tumors

1992 ◽  
Vol 29 (6) ◽  
pp. 490-494 ◽  
Author(s):  
K. Mross ◽  
K. Hamm ◽  
W. Schultze-Seemann ◽  
K. Burk ◽  
D. K. Hossfeld
Keyword(s):  
Plasma Concentrations ◽  
Intravesical Therapy ◽  
Bladder Tumors ◽  
Tissue Disposition

Intravesical Therapy with Adriamycin in Patients with Superficial Bladder Tumors

1980 ◽  
Vol 6 (3) ◽  
pp. 132-136 ◽  
Author(s):  
F. Edsmyr ◽  
T. Berlin ◽  
J. Boman ◽  
M. Duchek ◽  
P.L. Esposti ◽  
...  
Keyword(s):  
Intravesical Therapy ◽  
Bladder Tumors

Clonality of bladder tumors following radical nephroureterectomy: Against the field defect hypothesis.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 301-301
Author(s):  
Eugene K. Cha ◽  
John Sfakianos ◽  
Sasinya N. Scott ◽  
Paari Murugan ◽  
Gopa Iyer ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Point Mutations ◽  
Surgical Techniques ◽  
Median Number ◽  
Intravesical Therapy ◽  
Illustrative Case ◽  
Radical Nephroureterectomy ◽  
Bladder Tumors ◽  
Mutation Profile ◽  
Field Defect

301 Background: Urothelial carcinoma is characterized by multifocal and metachronous tumors. To explain this phenomenon, two hypotheses have been proposed: the ‘field defect’ hypothesis - urothelial cells are primed to undergo transformation by exposure to carcinogens, and the clonal, or ‘single progenitor cell,’ hypothesis - tumors arise from intraluminal seeding of transformed cells. Methods: To examine their clonal relationships, we compared the genomic profiles of primary upper tract urothelial carcinoma (UTUC) tumors and metachronous bladder tumors (intravesical recurrences) in patients treated with radical nephroureterectomy (RNU) and subsequent transurethral resection. Specimens were analyzed using a next-generation, targeted sequencing assay designed to identify point mutations, indels, and copy number alterations in 341 cancer-associated genes. Results: We analyzed 16 primary UTUC tumors and 41 intravesical recurrences in patients treated with RNU. The median number of intravesical recurrences per patient was 2 (range 1-7) and the interval from RNU to intravesical recurrence ranged from 3.5 months to 129 months. With an average sequencing coverage of 516x, we found strong evidence delineating the clonal relationship between primary UTUC tumors and subsequent bladder tumors. The majority of somatic mutations present in the primary UTUC tumors (median=7, range 4-39) were detected in all subsequent bladder tumors (128/146, 88%). In an illustrative case, one patient followed with periodic cystoscopy/cytology who had been NED for 5.5 years then developed 7 bladder tumors over the next 44 months, each with the identical mutation profile (8 mutations) as the primary tumor. Conclusions: We demonstrate that bladder tumors following RNU represent true intravesical recurrences, with almost all tumors sharing the same somatic mutation profile as the primary UTUC tumor. This has important implications for surgical techniques to minimize the risk of intraluminal seeding, the delivery of intravesical therapy following RNU, and the development of strategies employing systemic chemotherapy or targeted agents.

Intravesical Therapy of Noninvasive Bladder Tumors (stage Ta) with Doxorubicin: Initial Treatment Results and The Long-term Course

1988 ◽  
Vol 139 (6) ◽  
pp. 1212-1213 ◽  
Author(s):  
Finn Lundbeck ◽  
Eywin Bruun ◽  
Bjarne Finnerup ◽  
Ivan Strøyer Christophersen
Keyword(s):  
Initial Treatment ◽  
Intravesical Therapy ◽  
Treatment Results ◽  
Bladder Tumors

p53 STATUS DOES NOT PREDICT INITIAL CLINICAL RESPONSE TO BACILLUS CALMETTE-GUERIN INTRAVESICAL THERAPY IN T1 BLADDER TUMORS

1998 ◽  
Vol 159 (3) ◽  
pp. 1079-1084 ◽  
Author(s):  
FRANCK PAGES ◽  
THIERRY A. FLAM ◽  
ANNICK VIEILLEFOND ◽  
VINCENT MOLINIE ◽  
XAVIER ABEILLE ◽  
...  
Keyword(s):  
Clinical Response ◽  
Intravesical Therapy ◽  
Bacillus Calmette Guerin ◽  
Bladder Tumors ◽  
P53 Status

Early vs Delayed Radical Cystectomy Compared in Highgrade Superficial Bladder Tumors

2009 ◽  
Vol 76 (2) ◽  
pp. 83-86 ◽  
Author(s):  
V. Varca ◽  
A. Simonato ◽  
M. Esposito ◽  
A. Curotto ◽  
M. Orlandini ◽  
...  
Keyword(s):  
Overall Survival ◽  
Radical Cystectomy ◽  
Bladder Tumor ◽  
Progression Free Survival ◽  
Intravesical Therapy ◽  
Close Monitoring ◽  
Bladder Tumors ◽  
Free Survival ◽  
Muscle Invasive ◽  
Group B

Objectives The treatment of aggressive superficial TCC of the bladder remains controversial. In fact, although still classified as ‘superficial’, it has been shown that the biological characteristics of T1G3 bladder tumors are the same as those of the muscle-invasive group (T2 and above). Even with close monitoring and intensive intravesical therapy, the reported risk of muscle invasion in these patients is 53% and 1/3 die from this disease in the long-term. The aim of this study is to determine whether the timing of radical cystectomy affects the survival of patients with aggressive superficial bladder tumor. Methods We consider 74 patients who underwent radical cystectomy between November 1994 and October 2006 before a diagnosis of T1G3 bladder tumor. These patients were divided in 2 subgroups: group A (n=27, 25 M and 2 F) who underwent immediate radical cystectomy, and group B (n=47, 40 M and 7 F) who underwent other conservative treatments before radical cystectomy. Results The two subgroups were similar concerning age (66.29±8.37 yrs vs 66.87±8.6 yrs, respectively, p NS) and the timing of follow-up (respectively 77±45 vs 60±35 mths, p NS). Moreover, the progression-free survival was significantly higher in subgroup A (53.73±48.54 vs 31.94±35.19 mths, log-rank p<0.05) as well as the overall survival (59.73±45.37 vs 36.45±33.96 mths respectively, log-rank p<0.05). Comparing the histological examinations, the two subgroups were significantly different concerning the T stage (superficial tumors 14/27 vs 16/47, respectively, p<0.05; invasive tumors 13/27 vs 31/47, respectively, p<0.00005) and the lymphonodal dissemination (2N+/27 vs 11N+/47, respectively, p<<0.0005). Conclusions Delaying radical cystectomy for aggressive superficial bladder tumors leads to a worse progression-free survival; the overall survival is likely to be due also to an early lymphonodal dissemination, which occurs extending the timing between diagnosis and radical treatment.

p53 STATUS DOES NOT PREDICT INITIAL CLINICAL RESPONSE TO BACILLUS CALMETTE-GUERIN INTRAVESICAL THERAPY IN T1 BLADDER TUMORS

1998 ◽  
pp. 1079-1084 ◽  
Author(s):  
FRANCK PAGES ◽  
THIERRY A. FLAM ◽  
ANNICK VIEILLEFOND ◽  
VINCENT MOLINIE ◽  
XAVIER ABEILLE ◽  
...  
Keyword(s):  
Clinical Response ◽  
Intravesical Therapy ◽  
Bacillus Calmette Guerin ◽  
Bladder Tumors ◽  
P53 Status

An Overview of Intravesical Therapy for Superficial Bladder Tumors

1987 ◽  
Vol 138 (6) ◽  
pp. 1363-1368 ◽  
Author(s):  
Harry W. Herr ◽  
Vincent P. Laudone ◽  
Willet F. Whitmore
Keyword(s):  
Intravesical Therapy ◽  
Bladder Tumors

Adjuvant immunotheraphy in the treatment of superficial multicentric bladder tumors

1992 ◽  
Vol 59 (1_suppl) ◽  
pp. 176-178
Author(s):  
G. Lissoni ◽  
G. Galbiati ◽  
R. Borin ◽  
M. Ferruti ◽  
C. Milani
Keyword(s):  
Natural History ◽  
Bladder Tumor ◽  
Local Treatment ◽  
Intravesical Therapy ◽  
Bacillus Calmette Guerin ◽  
Bladder Tumors ◽  
Adjuvant Immunotherapy ◽  
Superficial Bladder Tumor ◽  
History Of

The authors report their results in adjuvant immunotherapy with B.C.G. after TUR for superficial and multicentric bladder tumors (Ta-T1). After TURB a cycle of intravesical immunotheraphy with 150 mg of BCG (Bacillus Calmette-Guerin) is performed once a week for 6 weeks, ther every 2 weeks for 6 times and finally once a month for 1 year. (16.5 months of treatment). Controls with CTM and cystoscopy are performed periodically. 63 patients have been treated: 20 (60.6%) are free from disease with follow-up of 18–36 months; 87.5% of patients who had BCG as immunotherapy after first TUR for bladder tumor, are free from disease. Comparing their results with experiences reported in literature with Mytomicin and Doxorubicin, the authors think that adjuvant immunotherapy with BCG is actually the best local treatment for these tumors. Some patients (25%) had slight troubles because of therapy but only in 3 cases (9.09%) treatment was stopped. In conclusion intravesical therapy with BCG significantly changes natural history of superficial bladder tumor, increasing the time free from disease (in our experience: 27 months).

Sign in / Sign up

Export Citation Format

Share Document